Connection

Nathan Dolloff to Proteasome Inhibitors

Back to Details
This is a "connection" page, showing publications Nathan Dolloff has written about Proteasome Inhibitors.
Nathan Dolloff
Connection Strength
2.431
Proteasome Inhibitors
  1. Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor. Eur J Med Chem. 2020 Jan 15; 186:111906.
    View in: PubMed
    Score: 0.649
  2. Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma. Leukemia. 2019 04; 33(4):1011-1022.
    View in: PubMed
    Score: 0.601
  3. Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. Oncotarget. 2017 May 30; 8(22):35863-35876.
    View in: PubMed
    Score: 0.547
  4. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance. Adv Cancer Res. 2015; 127:191-226.
    View in: PubMed
    Score: 0.472
  5. Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo. Leuk Res. 2020 01; 88:106271.
    View in: PubMed
    Score: 0.162
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.